A5058983441- Frailty in Older Adults
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Inflammatory Biomarkers in Disease Prognosis
- Wildlife Ecology and Conservation
- Breast Lesions and Carcinomas
- Colorectal Cancer Treatments and Studies
- Nutrition and Health in Aging
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Animal Behavior and Reproduction
- Lymphatic System and Diseases
- Glioma Diagnosis and Treatment
- Radiation Dose and Imaging
- Brain Metastases and Treatment
- Animal Ecology and Behavior Studies
- Advanced Breast Cancer Therapies
- Radiomics and Machine Learning in Medical Imaging
- S100 Proteins and Annexins
- Cancer-related cognitive impairment studies
- Management of metastatic bone disease
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Pharmacy and Medical Practices
Cedars-Sinai Medical Center
2023-2025
City of Hope
2015-2022
City Of Hope National Medical Center
2016-2019
Fox Chase Cancer Center
2019
Memorial Sloan Kettering Cancer Center
2016-2019
Roswell Park Comprehensive Cancer Center
2018-2019
Hospital Universitario Doctor Peset
2019
Dana-Farber Cancer Institute
2019
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
2019
Thomas Jefferson University Hospital
2018
Purpose Older adults are at increased risk for chemotherapy toxicity, and standard oncology assessment measures cannot identify those risk. A predictive model toxicity was developed (N = 500) that consisted of geriatric questions other clinical variables. This study aims to externally validate this in an independent cohort 250). Patients Methods age ≥ 65 years with a solid tumor, fluent English, who were scheduled receive new regimen recruited from eight institutions. Risk calculated (low,...
Limited tools exist to predict the risk of chemotherapy toxicity in older adults with early-stage breast cancer.Patients age ≥ 65 years stage I-III cancer from 16 institutions treated neoadjuvant or adjuvant were prospectively evaluated for geriatric and clinical features predictive grade 3-5 toxicity. Logistic regression best-subsets selection was used identify incorporate independent predictors into a model weighted variable scoring. Model performance using area under ROC curve (AUC)...
Abstract Background Previous research demonstrates longer survival for patients with lung-only metastatic pancreatic adenocarcinoma (mPDAC) compared to liver-only mPDAC. The objective of this study is understand the differences, impact chemotherapy, and associated genomic features mPDAC that isolated either liver or lung. Patients methods Longitudinal clinical outcomes molecular sequencing data were retrospectively analyzed across 831 PDAC all stages whose tumors first metastasized Survival...
The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy older women with breast cancer.We recruited 16 aged ≥ 60 years stage I-III cancers receiving (CT) 15 age- sex-matched healthy controls (HC). CT group underwent MRI the NIH Toolbox for Cognition testing prior (time point 1, TP1) within 1 month 2, TP2). HC same assessments at matched intervals. GMD evaluated voxel-based morphometry.The mean age 67 68.5 group....
Chemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with toxicity. efficacy depends on relative dose intensity (RDI), an RDI < 85% is associated worse overall survival. The pro-inflammatory (interleukin (IL)-6, C-reactive protein (CRP)) coagulation factors (D-dimer) serve as biomarkers aging. purpose this study to determine if these are reduced women stage I–III BC. This enrolled Prior adjuvant or neoadjuvant chemotherapy, peripheral blood...
Abstract Background: Older pts with BC receiving adjuvant tx are at increased risk of chemo tox; however, no BC-specific tool exists to quantify this risk. The Cancer and Aging Research Group (CARG) developed/validated a tox score for older all stages solid tumor. goals study were to: 1) build upon the CARG by developing/validating CARG-BC (a specific pts) 2) evaluate its association dose modifications, reduced relative intensity (RDI) hospitalizations. Methods: 501 age ≥65 stage I-III from...
Many species roost communally but the proximate causes and ultimate functions of this widespread behavior remain poorly understood. We studied communal roosts two undescribed harvestmen in genus Prionostemma Pocock 1903 at a Caribbean rainforest site southeastern Nicaragua. The are quite similar gross morphology differ body coloration, male genitalia, roosting behavior. One primarily on spiny palms while other species, which is darker inside buttress root cavities. In mark-recapture study,...
4024 Background: PDAC is an aggressive cancer and refractory to immunotherapy due its immunosuppressive tumor microenvironment (TME). Focal adhesion kinase (FAK) a master regulator of the TME associated with immune suppression. Our current randomized phase II trial evaluates use pembrolizumab, programmed cell death 1 (PD-1) checkpoint inhibitor, or without defactinib, FAK inhibitor (FAKi), as sequential neoadjuvant adjuvant therapy in patients high risk resectable PDAC. We hypothesize that...
Abstract Background Pro-inflammatory and coagulation factors serve as biomarkers of aging functional reserve. The purpose this study was to determine if pro-inflammatory (interleukin-6 [IL-6], C-reactive protein [CRP]), (D-dimer) were associated with pre-chemotherapy status in women stage I–III breast cancer. Patients Methods Prior chemotherapy initiation patients cancer, the following captured: IL-6, CRP, D-dimer blood levels, physical function measures including activities daily living...
Abstract Background: Older adults are less likely to be included in clinical trials leading the approval of novel cancer treatments. The Institute Medicine and ASCO have identified therapeutic phase II as a key research priority increase evidence base for older with cancer. While targeted therapies may represent toxic option patients, few studied their tolerability efficacy adults. Here, we present study (NCT01273610) combination trastuzumab lapatinib patients HER2+ metastatic breast (MBC),...
Abstract Background Older adults (≥65 years) with gastrointestinal (GI) cancers who receive chemotherapy are at increased risk of hospitalization caused by treatment-related toxicity. Geriatric assessment (GA) has been previously shown to predict toxicity in older undergoing chemotherapy. However, studies incorporating the GA specifically GI have limited. This study sought identify GA-based factors for toxicity–related among cancers. Patients and Methods We performed a secondary post hoc...
e18672 Background: By 2060, nearly a quarter of older adults in the US will identify themselves as Hispanic/Latino. We have previously developed self-administered GA tool which can be used to functional, psychological, social and cognitive vulnerabilities with cancer. Among English-speaking adults, answering this using tablet or paper/pencil takes median 15-21 minutes (min), < 10% need assistance complete it (Hurria, JOP 2016). However, has not been tested Spanish-speaking adults. assessed...
Abstract Background: Almost a quarter of older adults in the United States will identify themselves as Hispanic/Latino by 2060. Our group has previously developed and validated self-administered geriatric assessment tool which can be used to functional, psychological, social cognitive impairments among patients with various types cancer. Among English-speaking adults, completing this using paper/pencil or tablet takes median 15-21 minutes (min), &lt; 10% needing assistance answer it...
Abstract Background: Older adults with breast cancer receiving neo/adjuvant chemotherapy are at increased risk for toxicity and dose reductions, often leading to decreased relative intensity (dRDI &lt; 85%) potentially compromised benefits. Identifying which older patients projected have dRDI standard regimens could help optimize systemic treatment delivery completion. Methods: We prospectively enrolled aged ≥ 65 who were starting HER2-negative, stage I-III cancer. Geriatric assessment...
9539 Background: Chemo decreases the risk of relapse and mortality from BC. efficacy depends on RDI, patients (pts) who receive <85% RDI have poorer overall survival. Pro-inflammatory coagulation factors such as IL-6, CRP D-dimer serve biomarkers for aging. The utility these markers biologic correlates ability to deliver chemo (i.e. RDI) in pts with BC is unknown. This study was performed determine if prechemo correlate women stage I-III requiring chemo. Methods: a prospective longitudinal...
Abstract Background: Pro-inflammatory and coagulation factors serve as biomarkers of aging functional reserve. Chemotherapy (chemo) decreases the risk relapse mortality from breast cancer (BC); however, it comes with toxicity. The utility these markers biological for chemotherapy toxicity in patients BC is unknown. This study was performed to determine if pre-chemo IL-6, CRP D-dimer were associated women receiving adjuvant or neoadjuvant chemo. Methods: enrolled across spectrum Stage I-III...
e21523 Background: Older adults undergoing chemotherapy for GI cancers are at increased risk of HOS due to treatment related toxicity; however, there limited data regarding which individuals greatest risk. We therefore sought identify factors among older with receiving chemotherapy. Methods: performed a secondary analysis patients age ≥ 65 years cancer who participated in either 2 prospective studies used develop (n = 500) and validate 250) geriatric assessment (GA) based toxicity score...
10035 Background: The Institute of Medicine and ASCO identified key research priorities to improve the evidence base older adults with cancer, including need for therapeutic phase II trials. Here we present a study nab-paclitaxel in patients (pts) MBC, incorporating geriatric oncology principles design. Methods: Pts age ≥65 years MBC 0-1 chemotherapy (CT) lines received (100 mg/m 2 , 3 wks on, 1 wk off). completed assessment (GA) pre-CT measures function, comorbidity, cognition, nutrition,...